EUROPEAN CANCER RESEARCH Summit
May 3, 2021 | PORTO, PORTUGAL

PROGRAM (CET)

Please note that in this version of the program, the time is set as CET (Central European Time).

09:30-10:00 - REGISTRATION

10:00-10:30 - WELCOME AND OPENING SESSION/REMARKS
- Rui Henrique, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
- Julio E. Celis, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark
- Stella Kyriakides, European Commissioner for Health and Food Safety, European Union
- Marta Temido, Minister for Health, Portugal
- Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education & Youth, European Union
- Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal

10:30-10:50 - KEYNOTE SPEECHES

> Route To The Cancer Mission: A Shared View Of The Cancer Community On How To Succeed | Anton Berns, President of the European Academy of Cancer Sciences (EACS)
> The EU Cancer Mission | Walter Ricciardi, President, EU Cancer Mission Board, Brussels, Belgium

10:50-11:10 - COFFEE BREAK

11:10-13:10 - SESSION 1. INFRASTRUCTURE FOR TRANSLATIONAL RESEARCH
Chair: Ulrik Ringborg, Cancer Center Karolinska, Stockholm, Sweden

Presentations:
> Basic/preclinical research: Generating proof of concept clinical trials is the engine for translational cancer research | Alexander Eggermont, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
> The Comprehensive Cancer Centre: An essential infrastructure component | Simon Oberst, Cancer Research UK, Cambridge Center, Cambridge, UK
> Molecular and digital pathology is essential to develop personalized/precision cancer medicine | Fátima Carneiro, University of Porto, Porto, Portugal
> Immunotherapy: An expanding treatment modality | Laurence Zitvogel, Gustave Roussy Cancer Campus, Grand Paris, France
> Liquid biopsies: Expanding diagnostic procedures for both therapeutics and prevention | Olli Kallioniemi, Science for Life Laboratory, Stockholm, Sweden
> Acquisition of clinical and biological data: Implementation of computational sciences (Artificial Intelligence) | Jan Korbø, European Molecular Biology Laboratory, Heidelberg, Germany
> EC Knowledge Centre on Cancer | Guy Van den Eede, European Commission, Brussels, Belgium
13:10-13:40 - LUNCH

13:40-15:40 - SESSION 2. INFRASTRUCTURE FOR CLINICAL AND PREVENTION TRIALS
Chair: Josep Tabernero, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain

Presentations:
> Quality assurance of clinical trials structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials | Denis Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
> Molecular pathology for patient stratification in multicentre clinical trials | Paolo Nuciforo, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
> Genomics: From discovery to bench-side genomics | Emile Voest, The Netherlands Cancer Institute, Amsterdam, The Netherlands
> Modern Imaging in Oncology | Regina Beets-Tan, The Netherlands Cancer Institute, Amsterdam, The Netherlands
> Repeated biopsies (fine needle aspiration and liquid biopsies), biobanking and clinical trials registries with clinical and biological information | Benjamin Besse, Institute Gustave-Roussy, Grand Paris, France
> Development of innovative radiotherapy trials | Vincenzo Valentini, Policlinico Gemelli, Rome, Italy
> Coordination of clinical trials activities from proof-of-concept trials to practice-changing clinical trials: added value compared to present treatments | Elena Garralda, Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
> New concepts and opportunities in cancer prevention clinical trials | Elisabete Wiederpass, International Agency for Research on Cancer, Lyon, France
> The Molecular Tumour Board: a critical infrastructure for delivery of Precision Medicine | Júlio Oliveira, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate:
> Bettina Ryll, Cancer Mission Board member, Uppsala, Sweden
> Susan Galbraith, AstraZeneca, Cambridge, UK
> Fátima Cardoso, Champalimaud Clinical Center, Lisbon, Portugal
> José Carlos Machado, Institute for Investigation and Innovation in Health (i3S), Porto, Portugal

15:40-17:40 - SESSION 3. INFRASTRUCTURE FOR OUTCOMES RESEARCH
Chair: Joachim Schüz, International Agency for Research on Cancer, Lyon, France

Presentations:
> Outcomes research Infrastructure to support the development of primary prevention | Joachim Schüz, International Agency for Research on Cancer, Lyon, France
> Outcomes research infrastructure to support the development of cancer screening | Partha Basu, International Agency for Research on Cancer, Lyon, France
> Outcomes research infrastructure to support the assessment of clinical effectiveness of therapeutic innovations | Nils Wilking, Karolinska Institutet, Stockholm, Sweden
> Infrastructure support for cancer specific Health-Related Quality of Life research | Karen Steindorf, National Center for Tumour Diseases and German Cancer Research Center, Heidelberg, Germany
> Outcomes research infrastructure for survivorship research | Françoise Meunier, Former head of the European Organisation for Research and Treatment of Cancer, Brussels, Belgium
> Health economics as an integrated part of the cancer research continuum for prevention and therapeutics | Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden
> A case study: outcomes implementation and measurement in lung cancer | Marta Soares, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate:
> Jose M. Martin-Moreno, University of Valencia, Spain
> Florian Alexandru Nicula, Institute of Oncology, Cluj-Napoca, Romania (tbc)
> Matti Aapro, President of the European Cancer Organization, Brussels, Belgium
> Gennaro Ciliberto, Director of Digital Institute for Cancer Outcome Research (DIGICORE), Brussels, Belgium

17:40-17:45 - SESSION 4. OPINION ON CANCER
Eva Kondorosi, European Commission’s Group of Chief Scientific Advisors (GCSA), Brussels, Belgium

17:45-18:05 - SESSION 5. EU-USA CANCER RESEARCH COOPERATION
Chair: Michael Baumann, German Cancer Research Centre (DKFZ), Heidelberg, Germany
> Strategic development of precision cancer medicine in the US | Richard Schilsky, Past President and former Chief Medical Officer, American Society of Clinical Oncology, Alexandria, VA, USA

18:05-18:15 - PRESENTATION OF “PORTO DECLARATION ON CANCER RESEARCH”
Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal

18:15-18:30 - CLOSING REMARKS
> António Sousa Pereira, Rector, University of Porto, Porto, Portugal
> Rui Henrique, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
> Julio E. Celis, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark
> Patrick Child, Deputy Director General of Research & Innovation, European Commission, Brussels, Belgium
> Simona Kustec, Minister for Education, Science and Sport, Slovenia
> Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal